The overarching objective of our Rheumatology Research Group is to improve clinical outcomes for those with, and at risk of developing, rheumatoid arthritis (RA), Sjögren’s syndrome (SS) and systemic lupus erythematosus (SLE) by developing diagnostic tests, drugs, cell based therapies and lifestyle assessments to predict, prevent and reverse disease pathology.
A unique feature of our translational research is that we have pioneered a first in class,“process-driven pathway-focused” approach to the biology of inflammatory arthritis:
- To improve clinical outcomes for those with, and at risk of developing, rheumatoid arthritis (RA), Sjogren’s syndrome (SS) and systemic lupus erythematosus (SLE)
- To discover and improve tests used to make diagnoses and to predict disease course from the earliest stages of symptoms
- To explore therapeutic targeting of the tissue microenvironment and compare and contrast the biological processes underpinning the development, maintenance and resolution of inflammation
- To compare shared biological mechanisms across a number of traditionally independent organ based medical disciplines in order to develop biologically meaningful and therapeutically tractable process-driven links to other disease areas in inflammation biology